Skip to main content
SpringerLink
Log in

Haemodynamic Responses to Specific Renin-Angiotensin Inhibitors in Hypertension and Congestive Heart Failure

A Review

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Summary

The renin-angiotensin system is an important regulator of vascular resistance in many patients with hypertension and congestive heart failure. To quantitatively evaluate this contribution requires correlation of markers of the renin-angiotensin system with haemodynamic parameters, notably blood pressure, cardiac output, and calculated systemic vascular resistance. In addition, to determine ventricular loading properties, assessment of cardiac filling pressures is also required. The availability of specific pharmacological inhibitors of the renin-angiotensin system greatly enhances such correlation, as the haemodynamic consequence of blocking the renin-angiotensin system can then more fully identify its contribution. In the last decade, highly specific pharmacological inhibitors have become available to serve such a purpose. Renin inhibitory peptides, and renin-specific antibodies can block the rate-limiting step of the renin-angiotensin cascade: namely, the cleavage of 4 amino acids from the angiotensinogen substrate by renin. However, this method of blockade is still at the early stages of investigation. More readily available are converting enzyme inhibitors which block the formation of angiotensin II, the potent vasoconstrictor which mediates increased systemic vascular resistance, and angiotensin II analogues which compete with endogenous angiotensin II for vascular and adrenal receptors.

Although hypertension and chronic congestive heart failure are clinically distinct entities in many respects, their common bond is the fact that both pathological mechanisms are mediated by an increase of systemic vascular resistance. The implications of blocking the resulting vasoconstriction in both entities are therefore quite similar. This review summarises our present knowledge of the contribution of the renin-angiotensin system to the vasoconstriction of hypertension and congestive heart failure, and also summarises the haemodynamic consequences of such inhibition. The implications of the response to these specific pharmacological probes, as well as their limitations, are discussed. Their importance rests not only in their therapeutic application, but also in their contribution as probes for pathophysiological mechanisms of vasoconstriction in cardiovascular disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Ader, R.; Chatterjee, K.; Ports, T.; Brundage, B.; Hiramatsu, B. and Parmley, M.: Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibition. Circulation 61: 931–977 (1980).

    PubMed  CAS  Google Scholar 

  • Anderson, G.H.; Streeten, D.H.P. and Dalakos, T.G.: Pressor response to 1-Sar-8-Ala-angiotensin II (saralasin) in hypertensive subjects. Circulation Research 40: 243–250 (1977).

    PubMed  CAS  Google Scholar 

  • Antonaccio, M.J.: Angiotensin converting enzyme (ACE) inhibitors. Annual Review of Pharmacology and Toxicology 22: 57–87 (1982).

    PubMed  CAS  Google Scholar 

  • Arroyo, V.; Bosch, J.; Mauri, M.; Ribera, F.; Navarro-Lopez, F. and Rodes, J.: Effect of angiotensin-II blockade on systemic and hepatic haemodynamics and on the renin-angiotensin aldosterone system in cirrhosis with acsites. European Journal of Clinical Investigation 11: 221–229 (1981).

    PubMed  CAS  Google Scholar 

  • Awan, N.A.; Evenson, M.K.; Needham, K.E.; Win, A. and Mason, O.T.: Efficacy of oral angiotensin-converting enzyme inhibition with captopril therapy in severe chronic normotensive congestive heart failure. American Heart Journal 101: 22–31 (1981).

    PubMed  CAS  Google Scholar 

  • Bosche, J.; Arroyo, V.; Betriu, A.; Mas, A.; Carrilho, F.; Rivera, F.; Navarro-Lopez, F. and Rodes, J.: Hepatic hemodynamics and the renin-angiotensin-aldosterone system in cirrhosis. Gastroenterology 78: 92–99 (1980).

    Google Scholar 

  • Bravo, E.L. and Tarazi, M.C.: Converting enzyme inhibition with an orally active compound in hypertensive man. Hypertension 1: 39–46 (1979).

    PubMed  CAS  Google Scholar 

  • Brunner, D.B.; Desponds, G.; Biollaz, J.; Keller, I.; Ferber, F.; Gavras, H.; Brunner, H.R. and Schelling, J.L.: Effect of a new angiotensin converting enzyme inhibitor MK-421 and its lysine analogue on the components of the renin system in healthy subjects. British Journal of Clinical Pharmacology 11: 461 (1981).

    PubMed  CAS  Google Scholar 

  • Brunner, H.R.; Gavras, H. and Laragh, J.H.: Specific inhibition of the renin-angiotensin system: A key to understanding blood pressure regulation. Progress in Cardiovascular Disease 17: 87–98 (1974).

    CAS  Google Scholar 

  • Bühler, F.R.: Age and cardiovascular response adaptation. Determinants of an antihypertensive treatment concept primarily based on beta-blockers and calcium entry blockers. Hypertension 5 (Suppl. Ill): 94–100 (1983).

    Google Scholar 

  • Bumpus, F.M.; Sen, S.; Smeby, R.R.; Sweet, C; Ferrario, CM. and Khosla, M.C.: Use of angiotensin II antagonists in experimental hypertension. Circulation Research 32 (Suppl. 1): 150–158 (1973).

    PubMed  Google Scholar 

  • Burnier, M.; Biollaz, J.; Brunner, H.R.; Turini, B.A. and Gavras, H.: Comparison in normal volunteers of three converting enzyme inhibitors: RHC 3659, MK 421 and captopril. American Journal of Cardiology 49(6): 1550–1551 (1982).

    PubMed  CAS  Google Scholar 

  • Burton, J.; Cody, R.J.; Herd, J.A. and Haber, E.: Specific inhibition of renin by an angiotensinogen analog: Studies in sodium depletion and renin-dependent hypertension. Proceedings of the National Academy of Science (USA) 77: 5476–5479 (1980).

    CAS  Google Scholar 

  • Burton, J.; Cody, R.J.; Poulson, K.; Hartley, L.H.; Slater, E.E. and Haber, E.: The design of specific inhibitors of renin which are active in vivo; in Ebashi (Ed.) Advances in Pharmacology and Therapeutics (Pergamon Press, Oxford 1982).

    Google Scholar 

  • Burton, J.; Haber, E. and Poulsen, K.: The design of effective renin inhibitors; in Walter and Meienhofer (Eds) Peptides: Chemistry, Structure and Biology (Ann Arbor Science Publishers, Ann Arbour 1975).

    Google Scholar 

  • Cannon, P.J.: The kidney in heart failure. New England Journal of Medicine 296: 26–32 (1977).

    PubMed  CAS  Google Scholar 

  • Case, D.B.; Atlas, S.A.; Laragh, J.H.; Sealey, J.E.; Sullivan, P.A. and McKinstry, D.N.: Clinical experience with blockade of the renin-angiotensin-aldosterone system by an oral converting-enzyme inhibitor (SQ 14,226, captopril) in hypertensive patients. Progress in Cardiovascular Disease 21: 195–206 (1978).

    CAS  Google Scholar 

  • Case, D.B.; Wallace, J.M.; Keim, H.J.; Sealey, J.E. and Laragh, J.H.: Usefulness and limitations of saralasin, a partial competitive agonist of angiotensin II, for evaluating the renin and sodium factors in hypertensive patients. American Journal of Medicine 60: 825–846 (1976).

    PubMed  CAS  Google Scholar 

  • Case, D.B.; Wallace, J.M.; Keim, H.J.; Weber, M.A.; Sealey, J.E. and Laragh, J.H.: Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme. New England Journal of Medicine 296: 641–646 (1977).

    PubMed  CAS  Google Scholar 

  • Chidsey, CA.; Braunwald, E. and Morrow, A.G.: Catecholamine excretion and cardiac stores of norepinephrine in congestive heart failure. Circulation 39: 442–451 (1965).

    CAS  Google Scholar 

  • Chonko, A.M.; Bay, W.H.; Stein, J.H. and Ferris, T.F.: The role of renin and aldosterone in the salt retention of edema. American Journal of Medicine 63: 881–889 (1977).

    PubMed  CAS  Google Scholar 

  • Clough, D.P.; Collis, M.G.; Conway, J.; Hatton, R. and Keddie, J.R.: Interaction of angiotensin-converting enzyme inhibitors with the function of the sympathetic nervous system. American Journal of Cardiology 49: 1410–1414 (1982).

    PubMed  CAS  Google Scholar 

  • Cody, R.J.; Bravo, E.L.; Fouad, F.M. and Tarazi, R.C.: Cardiovascular reflexes during chronic converting enzyme inhibition and sodium depletion: The response to tilt in hypertensive patients. American Journal of Medicine 71: 422–426 (1981).

    PubMed  Google Scholar 

  • Cody, RJ.; Burton, J.; Evin, G.; Poulsen, K.; Herd, J.A. ańd Haber, E.: A substrate analog inhibitor of reinin that is effective in vivo. Biochemical and Biophysical Research Communications 97: 230–235 (1980a).

    PubMed  CAS  Google Scholar 

  • Cody, R.J.; Covit, A.B.; Schaer, G.L. and Laragh, J.H.: Evaluation of a long-acting converting enzyme inhibitor (enalapril) for the treatment of chronic congestive heart failure. Journal of the American College of Cardiology 1: 1154–1159 (1983a).

    PubMed  CAS  Google Scholar 

  • Cody, R.J.; Covit, A.B.; Schaer, G.L. and Laragh, J.H.: Estimation of angiotensin II receptor activity in chronic congestive heart failure. American Heart Journal (In press, 1984).

  • Cody, R.J.; Covit, A.B.; Schaer, G.L.; Sealey, J.E. and Laragh, J.H.: Renin-sodium mechanisms in chronic heart failure: Response to sodium balance studies. Circulation 66 (Suppl. II): 286 (1982e).

    Google Scholar 

  • Cody, R.J.; Covit, A.; Schaer, G. and Williams, G.: Captopril pharmacokinetics and the acute hemodynamic and hormonal response in patients with severe chronic congestive heart failure. American Heart Journal 104: 1180–1183 (1982a).

    PubMed  CAS  Google Scholar 

  • Cody, R.J.; Franklin, K.W.; Kluger, J. and Laragh, J.H.: Sympathetic responsiveness and plasma norepinephrine during therapy of chronic congestive heart failure with captopril. American Journal of Medicine 72: 791–797 (1982b).

    PubMed  CAS  Google Scholar 

  • Cody, RJ.; Franklin, K.W.; Kluger, J. and Laragh, J.H.: Mechanisms governing the postural response, and baroreceptor abnormalities in chronic congestive heart failure: Effects of acute and long-term converting enzyme inhibition. Circulation 66: 135–142 (1982c).

    PubMed  CAS  Google Scholar 

  • Cody, R.J.; Franklin, K.W. and Laragh, J.H.: Postural hypotension during tilt with chronic captopril therapy of severe congestive heart failure. American Heart Journal 103: 480–484 (1982d).

    PubMed  CAS  Google Scholar 

  • Cody, RJ. and Laragh, J.H.: The role of the renin-angiotensinaldosterone system in the pathophysiology of chronic heart failure; in Cohn (Ed.) Drug Therapy of Chronic Heart Failure (ADIS Press, New York 1983).

    Google Scholar 

  • Cody, R.J.; Laragh, J.H.; Case, D.B. and Atlas, S.A.: Renin system activity as a determinant of response to treatment in hypertension and heart failure. Hypertension 5(Suppl. Ill): 36–42 (1983b).

    CAS  Google Scholar 

  • Cody, RJ.; Rodger, R.F.; Hartley, L.H.; Burton, J. and Herd, J.A.: Acute hypertension in a non-human primate: Humoral and hemodynamic mechanisms. Hypertension 4: 219 (1982f).

    PubMed  CAS  Google Scholar 

  • Cody, R.J.; Schaer, G.L.; Covit, A.B.; Pondolfmo K. and William G.: Captopril kinetics in chronic congestive heart failure. Clinical Pharmacology and Therapeutics 32: 721–726 (1982g).

    PubMed  CAS  Google Scholar 

  • Cody, R.J.; Tarazi, R.C.; Bravo, E.L. and Fouad, F.M.: Hemodynamics of orally active converting enzyme inhibitor (SQ 14225) in hypertensive patients. Clinical Science and Molecular Medicine 55: 453–459 (1978).

    PubMed  Google Scholar 

  • Cody, RJ.; Tarazi, R.C.; Fouad, F.M. and Bravo, E.L.: Hemodynamics of a new angiotensin antagonist (Sar1, Thr8) A II, in hypertensive man. Circulation 61: 338–344 (1980b).

    PubMed  Google Scholar 

  • Cohn, J.N. and Luria, M.H.: Studies in clinical shock and hypotension: II. Hemodynamic effects of norepinephrine and angiotensin. J. Clin. Invest. 44: 1494–1501 (1965).

    PubMed  CAS  Google Scholar 

  • Collier, J.G.; Robinson, B.F. and Vane, J.R.: Reduction of pressor effects of angiotensin I in man by synthetic nonapeptide (B.P.A. 9A or SQ 20,881) which inhibits converting enzyme. Lancet 1: 72–74 (1983).

    Google Scholar 

  • Conway, J.; Hatton, R.; Keddie, J. and Dawes, P.: The role of angiotensin in the control of blood pressure during sodium depletion. Hypertension 1: 402–409 (1979).

    PubMed  CAS  Google Scholar 

  • Creager, M.A.; Halperin, J.L.; Bernard, D.B.; Faxon, D.P.; Melidossian, CD.; Gavras, H. and Ryan, T.J.: Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation 64: 483–489 (1981).

    PubMed  CAS  Google Scholar 

  • Curtiss, C; Cohn, J.N.; Vrobel, T. and Franciosa, J.A.: Role of the renin-angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 58: 763–770 (1978).

    PubMed  CAS  Google Scholar 

  • Cushman, D.W.; Cheung, H.S.; Sabo, E.F. and Ondetti, M.A.: Design of new antihypertensive drugs: Potent and specific inhibitors of angiotensin-converting enzyme. Progress in Cardiovascular Diseases 21: 176–182 (1978).

    PubMed  CAS  Google Scholar 

  • Davis, R.; Ribner, H.S.; Keung, E.; Sonnenblick, E.H. and Lejemtel, T.H.: Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. New England Journal of Medicine 301: 117–121 (1979).

    PubMed  CAS  Google Scholar 

  • De Carvalho, J.G.R.; Dunn, F.G.; Kern, D.C.; Chrysant, S.G. and Fröhlich, E.D.: Hemodynamic correlates of saralasin-induced arterial pressure changes. Circulation 57: 373–378 (1978).

    PubMed  Google Scholar 

  • Di Carlo, L.; Chatterjee, K.; Parmley, W.W.; Swedberg, K.; Atherton, B.; Curran, D. and Cucci, M: Enalapril: A new angiotensin-converting enzyme inhibitor in chronic heart failure: Acute and chronic hemodynamic evaluations. Journal of the American College of Cardiology 2: 865–871 (1983).

    Google Scholar 

  • DiSalvo, J.; Britton, S.; Galvas, P. and Sanders, T.W.: Effects of angiotensin I and angiotensin II on canine hepatic vascular resistance. Circulation Research 32: 85–92 (1973).

    CAS  Google Scholar 

  • Dunn, F.G.; Oigman, W.; Ventura, H.O.; Kobrin, I.; Messerll, F.H. and Fröhlich, E.D.: Enalapril improves systemic and renal hemodynamics and regresses left ventricular mass in essential hypertension. (Abstract.) Journal of the American College of Cardiology 1: 611 (1983).

    Google Scholar 

  • Dzau, V.J.; Colucci, W.S.; Williams, G.H.; Curfman, G.; Meggs, L. and Hollenberg, N.K.: Sustained effectiveness of converting enzyme inhibition in patients with severe congestive heart failure. New England Journal of Medicine 302: 1373–1379 (1980a).

    PubMed  CAS  Google Scholar 

  • Dzau, V.J.; Kopelman, R.I.; Barger, C.A. and Haber, E.: Reninspecific antibody for study of cardiovascular homeostasis. Science 207: 1091–1093 (1980b).

    PubMed  CAS  Google Scholar 

  • Dzau, V.J.; Lilly, L.; Swartz, S. and Packer, M.: Role of endogenous prostaglandins in circulating homeostasis in human heart failure. (Abstract.) Circulation 68 (Suppl. III): 129 (1982).

    Google Scholar 

  • Engel, S.L.; Schaeffer, T.R.; Gold, B.I. and Rubin, B.: Inhibition of pressor effects of angiotensin I and augmentation of depressor effects of bradykinin by synthetic peptides. Proceedings of the Society of Experimental Biology and Medicine 140: 240–244 (1972).

    CAS  Google Scholar 

  • Erdos, E.G.; Massion, W.H.; Downs, D.R. and Gecse, A.: Effect of the inhibition of angiotensin I converting enzyme in endotoxin and hemorrhagic shock. Proceedings of the Society of Experimental Biology and Medicine 145: 948–951 (1974).

    CAS  Google Scholar 

  • Ertl, G.; Klomer, R.A.; Alexander, R.W. and Braunwald, E.: Limitation of experimental infarct size by an angiotensin-converting enzyme inhibitor. Circulation 65: 40–48 (1982).

    PubMed  CAS  Google Scholar 

  • Fagard, R.; Amery, A.; Reybrouck, T.; Lijnen, P. and Billiet, L.: Acute and chronic systemic and pulmonary hemodynamic effects of angiotensin converging enzyme inhibition with captopril in hypertensive patients. American Journal of Cardiology 46: 295–300 (1980).

    PubMed  CAS  Google Scholar 

  • Fagard, R.; Bulpitt, C; Lijnen, P. and Amery, A.: Response of the systemic and pulmonary circulation to converting-enzyme inhibition (captopril) at rest and during exercise in hypertensive patients. Circulation 65: 33–39 (1982a).

    PubMed  CAS  Google Scholar 

  • Fagard, R.; Lijnen, P.; Vanhees, L. and Amery, A.: Hemodynamic response to converting enzyme inhibition at rest and exercise in humans. Journal of Applied Physiology 53: 576–581 (1982b).

    PubMed  CAS  Google Scholar 

  • Faxon, D.P.; Creager, M.A.; Halperin, J.L.; Gavras, H.; Coffman, J.D. and Ryan, T.J.: Central and peripheral hemodynamic effects of angiotensin inhibition in patients with refractory congestive heart failure. Circulation 61: 925–930 (1980).

    PubMed  CAS  Google Scholar 

  • Ferguson, R.K.; Brunner, H.K.; Turini, G.A.; Gavras, H. and McKinstry, D.N.: A specific orally active inhibitor of angiotensin-converting enzyme in man. Lancet 1: 775–778 (1977).

    PubMed  CAS  Google Scholar 

  • Ferguson, R.K.; Vlasses, P.H.; Swanson, B.N.; Mojaverian, P.; Hichens, M.; Irvin, J.D. and Huber, P.B.: Effects of enalapril, a new converting enzyme inhibitor, in hypertension. Clinical Pharmacology and Therapeutics 32: 48–53 (1982).

    PubMed  CAS  Google Scholar 

  • Feuerstein, G. and Cohen, S.: Modification by SQ 14225 of blood pressure and adrenal catecholamine response to hemorrhage. European Journal of Pharmacology 55: 203–206 (1979).

    PubMed  CAS  Google Scholar 

  • Folkow, B.: Structural changes: The vascular wall. Consequences of treatment. Hypertension 5(Suppl. III): 58–62 (1983).

    Google Scholar 

  • Fouad, F.M.; Ceimo, J.M.K.; Tarazi, R.C. and Bravo, E.L.: Contrasts and similarities of acute hemodynamic responses to specific antagonism of angiotensin II (Sar1, Thr8, All) and to inhibition of converting enzyme (captopril.). Circulation 61: 163–169 (1980).

    PubMed  CAS  Google Scholar 

  • Fouad, F.M.; Tarazi, R.C. and Bravo, E.L.: Cardiac and hemodynamic effects of enalapril. Journal of Hypertension 1 (Suppl. 1): 135–142 (1983).

    PubMed  CAS  Google Scholar 

  • Frank, M.J.; Nadimi, M.; Casanegra, P.; Stein, P. and Pekaar, R.: Effect of angiotensin on myocardial function. American Journal of Physiology 218: 1267–1274 (1980).

    Google Scholar 

  • Frohlich, E.D.: Hemodynamics of hypertension; in Genest et al. (Eds) Hypertension, pp. 15–48 (McGraw-Hill, New York 1977).

    Google Scholar 

  • Cagnon, J.A.; Rice, M.K. and Flamenbaum, W.: Effect of angiotensin converting enzyme inhibition on renal autoregulation. Proceedings of the Society of Experimental Biology and Medicine 146: 414–418 (1974).

    Google Scholar 

  • Gavras, H.; Biollaz, J.; Waeber, B.; Brunner, H.R.; Gavras, I. and Davies, R.O.: Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor “MK-421”. Lancet 2: 543–547 (1981).

    PubMed  CAS  Google Scholar 

  • Gavras, H.; Faxon, D.P.; Berkoben, J.; Brumner, H.R. and Ryan, T.J.: Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation 58: 770–776 (1978).

    PubMed  CAS  Google Scholar 

  • Goldsmith, S.R.; Francis, G.S.; Cowley, A.W.; Levine, T.B. and Cohn, J.N.: Increased plasma arginine vasopressin levels in patients with congestive heart failure. Journal of the American College of Cardiology 1: 1385–1390 (1983).

    PubMed  CAS  Google Scholar 

  • Haber, E.: Position paper: New approaches to renin system blockade; in Laragh et al. (Eds) Frontiers in Hypertension Research, pp. 583–591 (Springer-Verlag, New York 1981).

    Google Scholar 

  • Hall, M.M.; Khosla, M.C.; Khairallah, P.A. and Bumpus, F.M.: Angiotensin analogs: The influence of sarcosine substituted in position 1. Journal of Pharmacology and Experimental Therapeutics 188: 222–228 (1974).

    PubMed  CAS  Google Scholar 

  • Halperin, J.L.; Faxon, D.P.; Creager, M.A.; Bass, T.A.; Melidossian, CD.; Gavras, H. and Ryan, T.J.: Coronary hemodynamic effects of angiotensin inhibition by captopril and teprotide in patients with congestive heart failure. American Journal of Cardiology 50: 967–972 (1982).

    PubMed  CAS  Google Scholar 

  • Hermiller, J.B.; Bambach, D.; Thompson, M.J.; Huss, P.; Fontana, M.E.; Magorien, R.D.; Unverferth, D.V. and Leier, C.V.: Vasodilators and prostaglandin inhibitors in primary pulmonary hypertension. Annals of Internal Medicine 97: 480–489 (1982).

    PubMed  CAS  Google Scholar 

  • Hollenberg, N.K.; Williams, G.H.; Burger, B.; Ishikawa, I. and Adams, D.F.: Blockade and stimulation of renal, adrenal and vascular angiotensin II receptors with 1-Sar, 8-Ala, angiotensin II in normal man. Journal of Clinical Investigation 57: 39–46 (1976).

    PubMed  CAS  Google Scholar 

  • Hricik, D.E.; Browning, P.J.; Kopelman, R.; Goorno, W.E.; Madias, N.E. and Dzau, V.J.: Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenosis or renal-artery stenosis in a solitary kidney. New England Journal of Medicine 308: 373–376 (1983).

    PubMed  CAS  Google Scholar 

  • Ibsen, H.; Kappelgaard, A.M.; Nielsen, M.D. and Giese, J.: The effect of angiotensin II blockade by saralasin (l-sar-8-ala-angiotensin II) in normal man. European Journal of Clinical Pharmacology 14: 171–176 (1978).

    PubMed  CAS  Google Scholar 

  • Ikram, H.; Chan, W.; Espiner, E.A. and Nicholls, M.G.: Haemodynamics and hormone responses to acute and chronic frusemide therapy in congestive heart failure. Clinical Science and Molecular Medicine 59: 443–449 (1980).

    CAS  Google Scholar 

  • Imai, Y.; Abe, K.; Seino, M.; Haruyama, T.; Tazima, J.; Yoshinaga, K. and Sekingo, H.: Captopril attenuates pressor responses to norepinephrine and vasopressin through depletion of endogenous angiotensin II. American Journal of Cardiology 49: 1537–1539 (1982).

    PubMed  CAS  Google Scholar 

  • Johnston, C.I.; Clappison, B.; McGrath, B.P.; Matthews, P.G.; Millar, J.A. and Anderson, W.P.: Kallirenin, kinins and blood pressure - effects of angiotensin-converting enzyme inhibition. Progress in Biochemistry and Pharmacology 17: 123–133 (1980).

    CAS  Google Scholar 

  • Keim, G.R.; Kirpan, A.E.; Peterson, A.E.; Murphy, B.F.; Hassert, G.L. and Poutsiaka, J.W. (Introduced by B. Rubin): Inhibition of angiotensin I-initiated hemodynamic changes in anesthesized dogs by a synthetic nonapeptide (36413). Proceedings of the Society for Experimental and Biochemical Medicine 140: 149–152 (1971).

    Google Scholar 

  • Khosla, M.C.; Hall, M.M.; Smeby, R.R. and Bumpus, F.M.: Agonist and antagonist relationships in 1-and 8-substituted analogs of angiotensin II. Journal of Medicinal Chemistry 17: 1156–1160 (1974).

    PubMed  CAS  Google Scholar 

  • Kluger, J.; Cody, R.J. and Laragh, J.H.: The contributions of sympathetic tone and the renin-angiotensin system to severe chronic congestive heart failure: Response to specific inhibition. American Journal of Cardiology 49: 1667 (1982).

    PubMed  CAS  Google Scholar 

  • Knepel, W. and Meyer, D.K.: Influence of converting enzyme inhibition on the release of vasopressin induced by angiotensin. British Journal of Pharmacology 71: 337–341 (1980).

    PubMed  CAS  Google Scholar 

  • Koike, H.; Ito, K.; Miyamoto, M. and Nishino, H.: Effects of long-term blockade of angiotensin converting enzyme with captopril (SQ 14,225) on hemodynamics and circulating blood volume in SHR. Hypertension 2: 299–303 (1980).

    PubMed  CAS  Google Scholar 

  • Kubo, S.H. and Cody, R.J.: Postural autoregulation in chronic heart failure: Hemodynamic and hormonal factors. Journal of the American College of Cardiology 1: 710 (1983).

    Google Scholar 

  • Laragh, J.H.: Hormones in the pathogenesis of congestive heart failure: Vasopressin, aldosterone, and angiotensin II. Circulation 25: 1015–1023 (1962).

    PubMed  CAS  Google Scholar 

  • Laragh, J.H.: The renin system in high blood pressure, from disbelief to reality: Converting-enzyme blockade for analysis and treatment. Progress in Cardiovascular Diseases 21: 159–166 (1978).

    PubMed  CAS  Google Scholar 

  • Laragh, J.H. and Sealey, J.E.: The renin-angiotensin aldosterone hormonal system and regulation of sodium, potassium, and blood pressure homeostasis; in Orloff and Berliner (Eds) Handbook of Renal Physiology, Section 8, pp. 831–908 (American Physiological Society, Washington 1973).

    Google Scholar 

  • Levine, T.B. and Cohn, J.N.: Determinants of acute and long-term response to converting enzyme inhibitors in congestive heart failure. American Heart Journal 104: 1159–1164 (1982).

    PubMed  CAS  Google Scholar 

  • Levine, T.B.; Franciosa, J.A. and Cohn, J.N.: Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation 62: 35–41 (1980).

    PubMed  CAS  Google Scholar 

  • Millar, J.A.; Derkx, F.H.; McLean, K. and Reid, J.L.: Pharmacodynamics of converting enzyme inhibition: The cardiovascular, endocrine and autonomic effects of MK 421 (enalapril) and MK 521. British Journal of Clinical Pharmacology 14: 347–355 (1982).

    PubMed  CAS  Google Scholar 

  • Munoz-Ramirez, H.; Khosla, M.C.: Bumpus, F.M. and Khairallah, P.A.: Hypotensive effect of (Sar1, Thr8) angiotensin II in spontaneously hypertensive sodium-depleted rats. American Journal of Physiology 234: H447–H453 (1978).

    PubMed  CAS  Google Scholar 

  • Mookherjee, S.; Obeia, A.; Warner, R.; Anderson, G.; Eich, R. and Smulyan, H.: Systemic and pulmonary hemodynamic effects of saralasin infusion in hypertension. American Journal of Cardiology 42: 987–995 (1978).

    PubMed  CAS  Google Scholar 

  • McCaa, R.E.: Studies in vivo with angiotensin I converting enzyme (kininase II) inhibitors. Federation Proceedings 38: 2783–2787 (1979).

    PubMed  CAS  Google Scholar 

  • Needleman, P.; Douglas Jr, J.R.; Jakschik, B.A.; Blumberg, A.L.; Isakson, P.C. and Marshall, G.R.: Angiotensin antagonists as pharmacological tools. Federation Proceedings 35: 2488–2493 (1976).

    PubMed  CAS  Google Scholar 

  • Needleman, P.; Johnson Jr, E.M.; Vine, W.; Flanigan, E. and Marshall, G.R.: Pharmacology of antagonists of angiotensin I and II. Circulation Research 31: 862–867 (1972).

    PubMed  CAS  Google Scholar 

  • Ng, K.K.F. and Vane, J.R.: Fate of angiotensin I in the circulation. Nature 218: 144–150 (1968).

    PubMed  CAS  Google Scholar 

  • Niarchos, A.P.; Pickering, T.G.; Case, D.B.; Sullivan, P. and Laragh, J.H.: Role of the renin-angiotensin system in blood pressure regulation. The cardiovascular effects of converting enzyme inhibition in normotensive subjects. Circulation Research 45: 829–837 (1979).

    PubMed  CAS  Google Scholar 

  • Niarchos, A.P.; Pickering, T.G.; Wallace, J.M.; Case, D.B. and Laragh, J.H.: Hemodynamic effects of the converting enzyme inhibitor teprotide in normal- and high-renin hypertension. Clinical Pharmacology and Therapeutics 28: 592–601 (1980).

    PubMed  CAS  Google Scholar 

  • Noth, R.H.; Tan, S.Y. and Mulron, P.J.: Effects of angiotensin II blockade by saralasin in normal man. Journal of Clinical Endocrinology and Metabolism 45: 10–15 (1977).

    PubMed  CAS  Google Scholar 

  • Ondetti, M.A.; Rubin, B. and Cushman, D.W.: Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 196: 441–443 (1977).

    PubMed  CAS  Google Scholar 

  • Ondetti, M.A. Williams, N.J.; Sabo, E.F.; Pluscec, J.; Weaver, E.R. and Kocy, O.: Angiotensin-converting enzyme inhibitors from the venom of Bothrops jaracaca. Isolation, elucidation of structure and synthesis. Biochemistry 10: 4033–4039 (1971).

    PubMed  CAS  Google Scholar 

  • Oparil, S.; Koerner, T. and O’Donoghue, J.K.: Mechanism of angiotensin I converting enzyme inhibition by SQ20,881 (less than glu-trp-pro-arg-pro-gln-ile-pro-pro) in vivo. Further evidence for extrapulmonary conversion. Hypertension 1: 13–22 (1979).

    PubMed  CAS  Google Scholar 

  • Peach, M.J.: Renin-Angiotensin system: Biochemistry and mechanisms of action. Physiological Reviews 57: 313–370 (1977).

    PubMed  CAS  Google Scholar 

  • Poulsen, K.; Burton, J. and Haber, E.: Competitive inhibitors of renin. A review. Progress in Biochemistry and Pharmacology 12: 135–141 (1976).

    CAS  Google Scholar 

  • Powers, E.R.; Bannerman, K.S.; Stone, J.; Reison, D.S.; Escala, EX.; Kalischer, A.; Weiss, M.B.; Sciacca, R.R. and Cannon, P.J.: The effect of captopril on renal, coronary, and systemic hemodynamics in patients with severe congestive heart failure. American Heart Journal 104: 1203–1210 (1982).

    PubMed  CAS  Google Scholar 

  • Preibisz, J.J.; Sealey, J.E.; Laragh, J.H.; Cody, R.J. and Weksler, B.: Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 5(Suppl. I): 129–138 (1983).

    Google Scholar 

  • Prida, S.E.; Kubo, S.H.; Laragh, J.H. and Cody, R.J.: Evaluation of calcium-mediated vasoconstriction in chronic congestive heart failure. American Journal of Medicine 75: 795–800 (1983).

    PubMed  CAS  Google Scholar 

  • Reid, I.A.; Morris, B.J. and Ganong, W.F.: The renin-angiotensin system. Annual Review of Physiology 40: 377–410 (1978).

    PubMed  CAS  Google Scholar 

  • Romankiewicz, J.A.; Brogden, R.N.; Heel, R.C.; Speight, T.M. and Avery, G.S.: Captopril: An update review of its pharmacological properties and therapeutic efficacy in congestive heart failure. Drugs 25: 6–40 (1983).

    PubMed  CAS  Google Scholar 

  • Rubin, B.; Laffan, R.J.; Kotler, D.G.; O’Keefe, E.H.; Demaio, D.A. and Goldberg, M.E.: SQ 14,225 (D-3-mercapto-2-meth-ylpropanoyl-L-prpline.): A novel orally active inhibitor of angiotensin I-converting enzyme. Journal of Pharmacology and Experimental Therapeutics 204: 271–280 (1978).

    PubMed  CAS  Google Scholar 

  • Sancho, J.; Re, R.; Burton, J.; Barger, A.C. and Haber, E.: The role of the renin angiotensin aldosterone system in cardio-vascular homeostasis in normal human subjects. Circulation 53: 400–405 (1976).

    PubMed  CAS  Google Scholar 

  • Saruta, T.; Suzuki, H.; Okuno, T. and Kondo K.: Effects of angiotensin-converting enzyme inhibitors on the vascular response to norepinephrine. Am. J. Cardiol. 49: 1535–1536 (1982).

    PubMed  CAS  Google Scholar 

  • Sharpe, D.N. and Coxon, R.: Hemodynamic effects of captopril in chronic heart failure: Efficacy of low-dose treatment and comparison with prazosin. American Heart Journal 104: 1164–1171 (1982).

    PubMed  CAS  Google Scholar 

  • Shepherd, A.N.; Campbell, B.C. and Reid, J.L.: Effects of captopril, an angiotensin-converting enzyme inhibitor, in normotensive sodium-replete volunteers. Journal of Cardiovascular Pharmacology 4: 381–387 (1982).

    PubMed  CAS  Google Scholar 

  • Skeggs, J.T.; Lentz, K.E.; Kahn, J.R. and Hochstrasser, H.: Kinetics of the reaction of renin with nine synthetic peptide substrates. Journal of Experimental Medicine 128: 13–34 (1968).

    PubMed  CAS  Google Scholar 

  • Soffer, R.L. and Sonnenblick, E.H.: Physiologic, biochemical, and immunologic aspects of angiotensin-converting enzyme. Progress in Cardiovascular Diseases 21: 167–175 (1978).

    PubMed  CAS  Google Scholar 

  • Stein, J.H. and Ferris, T.F.: The physiology of renin. Archives of Internal Medicine 131: 860–872 (1973).

    PubMed  CAS  Google Scholar 

  • Streeten, D.H.P.; Anderson, G.H.; Freiberg, J.M. and Dalakos, T.G.: Use of an angiotensin II antagonist (saralasin) in the recognition of “angiotensinogenic” hypertension. New England Journal of Medicine 202: 657–662 (1975).

    Google Scholar 

  • Sugawara, S. and Zimmerman, B.G.: Influence of angiotensin antagonists on renal vascular resistance and prostaglandin E release. Clinical and Experimental Hypertension 1: 11–24 (1978).

    PubMed  CAS  Google Scholar 

  • Sullivan, J.M.; Ginsburg, G.A.; Ratts, T.E.; Johnson, J.G.; Barton, B.R.; Kraus, D.H.; McKinstry, D.N. and Muirhead, E.E.: Hemodynamic and antihypertensive effects of captopril, an orally active angiotensin converting enzyme inhibitor. Hypertension 1: 397–401 (1979).

    PubMed  CAS  Google Scholar 

  • Swartz, S.L. and Williams, G.H.: Angiotensin-converting enzyme inhibition and prostaglandins. American Journal of Cardiology 49: 1405–1409 (1982).

    PubMed  CAS  Google Scholar 

  • Sweet, C.S.; Gross, D.M.; Arbegast, P.T.; Gaul, S.L.; Britt, P.M.; Ludden, CT.; Weitz, D. and Stone, C.A.: Antihypertensive activity of N-[(S)-l(ethoxycarbonyl)-3-phenylpropyl]-L-Ala-L-Pro (MK-421), an orally active converting enzyme inhibitor. Journal of Pharmacology and Experimental Therapeutics 216: 558–566 (1981).

    PubMed  CAS  Google Scholar 

  • Szelke, M.; Leckie, B.J.; Tree, M.; Brown, A.; Grant, J.; Hallett, A.; Hughes, M; Jones, D.M. and Lever, A.F.: H-77: A potent new renin inhibitor. In vitro and in vivo studies. Hypertension 4: 59–69 (1982).

    PubMed  CAS  Google Scholar 

  • Tarazi, R.C.; Bravo, E.L.; Fouad, F.M.; Omvik, P. and Cody, R.J.: Hemodynamic and volume changes associated with captopril. Hypertension 2: 576 (1980).

    PubMed  CAS  Google Scholar 

  • Tarazi, R.C.; Fouad, F.M.; Ceimo, J.K. and Bravo, E.L.: Renin, aldosterone and cardiac decompensation: Studies with an oral converting enzyme inhibitor in heart failure. American Journal of Cardiology 44: 1013–1018 (1979).

    PubMed  CAS  Google Scholar 

  • Textor, S.C.; Brunner, H.R. and Gavras, H.: Converting enzyme inhibition during chronic angiotensin II infusion in rats. Evidence against a nonangiotensin mechanism. Hypertension 3: 269–276 (1981).

    PubMed  CAS  Google Scholar 

  • Textor, S.C; Tarazi, R.C.; Novick, A.C.; Bravo, E.L. and Fouad, F.M.: Regulation of renal hemodynamics and glomerular filtration rate in patients with renovascular hypertension during converting enzyme inhibition with captopril. American Journal of Medicine (In press, 1984).

  • Thomas, J.A. and Marks, B.H.: Plasma norepinephrine in congestive heart failure. American Journal of Cardiology 41: 233–243 (1978).

    PubMed  CAS  Google Scholar 

  • Thurston, H. and Swales, J.D.: Action of angiotensin antagonists and antiserum upon the pressor response to renin: Further evidence for the local generation of angiotensin II. Clinical Science and Molecular Medicine 46: 273–276 (1974).

    PubMed  CAS  Google Scholar 

  • Topic, N.; Kramer, B. and Massie, B.: Acute and long-term effects of captopril on exercise cardiac performance and exercise capacity in congestive heart failure. American Heart Journal 104: 1172–1179 (1982).

    PubMed  CAS  Google Scholar 

  • Turini, G.A.; Brunner, H.R.; Ferguson, R.K.; Rivier, J.L. and Gavras, H.: Congestive heart failure in normotensive man. Haemodynamics, renin and angiotensin II blockade. British Heart Journal 40: 1134–1139 (1978).

    PubMed  CAS  Google Scholar 

  • Turker, R.K.; Page, I.H. and Bumpus, F.M.: Antagonists of angiotensin II; in Bumpus and Page (Eds) Angiotensin, pp. 162–169 (Springer, New York 1974).

    Google Scholar 

  • Waeber, B.; Gavras, I.; Brunner, H.R.; Cook, CA.; Charocopos, F. and Gavras, H.P.: Prediction of sustained antihypertensive efficacy of chronic captopril therapy: Relationships to immediate blood pressure response and control plasma renin activity. American Heart Journal 103: 384–390 (1982)

    PubMed  CAS  Google Scholar 

  • Wallace, J.M.; Case, D.B.; Laragh, J.H.; Keim, HJ.; Drayer, J.I.M. and Sealey, J.E.: The immediate pressor response to saralasin in man: A test of angiotensin II receptor vacancy. Circulation Research 44: 38–44 (1979).

    PubMed  CAS  Google Scholar 

  • Wallace, J.M.; Keim, J.H.; Case, D.B.; Lopez, J. and Laragh, J.H.: Reduction of cardiac output with angiotensin blockade in hypertension. (Abstract) Clinical Research 24: 244A (1976).

    Google Scholar 

  • Watkins Jr, L; Burton, J.A.; Haber, E.; Cant, J.R.; Smith, T.W. and Barger, A.C.: The renin-angiotensin-aldosterone system in congestive failure in conscious dogs. Journal of Clinical Investigation 57: 1606–1617 (1976).

    PubMed  CAS  Google Scholar 

  • Williams, G.H. and Hollenberg, N.K.: Accentuated vascular and endocrine response to SQ 20881 in hypertension. New England Journal of Medicine 297: 184–188 (1977).

    PubMed  CAS  Google Scholar 

  • Williams, G.M.; Davis, J.O.; Freeman, R.H.; DeForrest, J.M.; Seymour, A.A. and Rowe, B.P.: Effects of the oral converting enzyme inhibitor SQ 14225 in experimental high output failure. American Journal of Physiology 236: 541–545 (1979).

    Google Scholar 

  • Yamamoto, M.; Turker, R.K.; Khairallah, P.A. and Bumpus, F.M.: A potent competitive antagonist of angiotensin II. European Journal of Pharmacology 18: 316–322 (1972).

    PubMed  CAS  Google Scholar 

  • Yang, H.Y.T.; Erdös, E.G. and Levin, Y.: A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochemica et Biophysica Acta 214: 374–376 (1970).

    CAS  Google Scholar 

  • Zusman, R.; Christensen, D.; Burton, J.; Nussberger, J.; Dodds, A. and Haber, E.: Hemodynamic effects of a competitive renin inhibitory peptide in man: Evidence for multiple mechanisms of action. (Abstract.) Clinical Research 31: 538A (1983).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine (Cardiology) and Pharmacology, Cardiology Division, Section J-3, The New York Hospital-Cornell University Medical Center, 525 East 68th Street, New York, New York, 10021, USA

    Robert J. Cody

Authors
  1. Robert J. Cody
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cody, R.J. Haemodynamic Responses to Specific Renin-Angiotensin Inhibitors in Hypertension and Congestive Heart Failure. Drugs 28, 144–169 (1984). https://doi.org/10.2165/00003495-198428020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-198428020-00004

Keywords

Search

Navigation